|
Volumn 66, Issue 2, 2006, Pages 440-441
|
Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: New treatment for global dangers [4]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ATORVASTATIN;
CYTOCHROME P450;
PRAVASTATIN;
ROSUVASTATIN;
SIMVASTATIN;
CLINICAL PRACTICE;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSLIPIDEMIA;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL SYMPTOM;
HAZARD;
HEPATITIS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPOTHESIS;
LABORATORY TEST;
LETTER;
MORBIDITY;
MORTALITY;
MUSCLE DISEASE;
NON ALCOHOLIC STEATOHEPATITIS;
PATHOGENESIS;
PRIORITY JOURNAL;
UPREGULATION;
HUMAN IMMUNODEFICIENCY VIRUS;
|
EID: 28844465375
PISSN: 03069877
EISSN: None
Source Type: Journal
DOI: 10.1016/j.mehy.2005.09.003 Document Type: Letter |
Times cited : (6)
|
References (6)
|